Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases November 5, 2026 8:30 AM ESTCompany ParticipantsLuis Peña - Founder,... Evommune, Inc. (EVMN) Discusses In Licensing of EVO570 for Autoimmune Diseases November 5, 2026 8:30 AM EST Luis Peña - Founder, President, CEO & Director Good morning, and thank you…
European AIDS Treatment Group Contagion Live | Half of long COVID patients substantially improve within 3 years Approximately half of patients with long COVID sustained substantial symptom improvement and reported good quality of life within 3 years of acute infection and over a…
Winan van Houdt, Surgical Oncologist at Antoni van Leeuwenhoek/the Netherlands Cancer Institute, shared on LinkedIn: “A privilege it was to be invited to the Spanish ‘chirurgendagen’ to discuss the rationale behind neoadjuvant strategies for soft tissue sarcomas. Updating our…
The Best Interest Test in Real Life Mom won out, and the kids went vaccine-free. Then all three children became seriously ill; two were hospitalized with a preliminary diagnosis of measles. Measles tests came back negative, but the quirky backdrop…
In July 2014, a man sick with Ebola flew from Liberia into Lagos, Nigeria, one of Africa’s largest and busiest cities. One imported case in a place like that could have sparked an urban epidemic. Instead, Nigeria stopped the outbreak at…
The effects of long-term ketamine abuse have been highlighted by a coroner at the inquest of a 25-year-old Ringwood man. Oliver Henry Brockway, who was using the class B drug daily, died on 18th December last year. Winchester Coroners’ Court heard…
That word no longer applies. But the launch figures are only the most visible proof of something deeper: a molecular mechanism that may ultimately reshape treatment for the full spectrum of RAS-driven cancers — an addressable patient population vastly larger than…
The FDA has granted breakthrough therapy designation to enzomenib (DSP-5336) for the treatment of patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.1 Enzomenib is an investigational, oral, small molecule inhibitor of the protein interaction between menin and lysine KMT2A, an…
PD-1 inhibitors harness your immune system to shrink tumors Healthcare provider getting a patient ready to receive immunotherapy If you have advanced nonmelanoma skin cancer, you may have heard of immunotherapy. It’s quickly become an option for managing advanced cutaneous…
Pipelines, trials, approvals, safety, manufacturing, and next‑gen therapies.
An article joins this feed when it matches these terms. Each one is also a search of its own.